VEXAS syndrome: complete molecular remission after hypomethylating therapy

Since its first description in 2020, the VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), a genetically defined auto-inflammatory disease associated with hematological abnormalities, has gained increasing attention [1]. With 1:4000–1:14000 cases in the general population [2], the disease prevalence is much higher than initially expected. Clinical inflammatory manifestations are variable and often resistant to conventional immunosuppressive treatments. The majority of patients exhibit hematological abnormalities, including myelodysplastic neoplasm (MDS), macrocytic anemia, monoclonal gammopathy, and multiple myeloma [3]. Disease pathogenesis is linked to a loss of UBA1 function by acquired somatic mutations, most frequently affecting methionine 41 (p.M41) of the UBA1 gene, which codes for the E1 enzyme that regulates protein ubiquitination. Reduced ubiquitination mediates activation of the innate immune system and synthesis of proinflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-8, interferon, and tumor necrosis factor alpha [1], which contribute to the inflammatory phenotype of VEXAS syndrome.

Various therapeutic strategies have been described in case studies, ranging from steroids over azacitidine [4, 5] to ruxolitinib [6] and allogeneic hematopoietic cell transplantation (alloHCT) [7, 8]. The latter has been considered the only curative treatment option so far. Here we report for the first time complete molecular clearance of the underlying UBA1 mutation in two VEXAS patients (Table 1) who underwent treatment with the hypomethylating agent azacitidine (5-Aza), leading to treatment de-escalation. Written informed consent for clinical follow-up and detailed molecular diagnostics were obtained from both patients before treatment start.

To our knowledge, this is the first report describing complete molecular clearance of the UBA1-mutant clone in two VEXAS patients outside the context of alloHCT. While some authors have reported the suppression of the UBA1-mutant clone after HMA therapy [10], complete molecular clearance had not been observed until yet.

To further corroborate the depth of remission, we performed molecular monitoring using ultradeep NGS with a detection limit of 0.1% (median coverage > 100,000 reads) in CD34-selected peripheral blood (pB) (Fig. 1), which has a calculated overall sensitivity of 0.01–0.001% [9], indicating a very deep molecular clearance of the mutation.

Azacitidine, a hypomethylating agent approved for high-risk MDS and commonly recommended for patients with MDS and autoinflammatory features [4], has already been successfully used to treat autoinflammatory symptoms in VEXAS syndrome [4, 5]. Besides direct cytotoxic effects, azacitidine modulates the cytokine profile with downregulation of proinflammatory cytokines and impacts the bone marrow microenvironment [11], which might contribute to its positive effect on autoinflammatory sequelae.

Notably, steroids could be tapered within 2 months of treatment indicating that 5-Aza alone was sufficient to maintain remission in these patients. Nevertheless, the underlying mechanism by which 5-Aza impacts the UBA1 clonal burden is not clear, although direct cytotoxic effects have been described and a synthetic lethal interaction with the UBA1 clone has been speculated [12]. Prospective studies are necessary to clarify which VEXAS patients will benefit mostly from hypomethylating therapy, since different mutations may lead to differences in prognosis, phenotype, or even treatment responses.

To date, the three most common mutations in VEXAS syndrome impact methionine 41 in exon 3 of the UBA1 gene, namely p.M41Thr (c.122 T > C), p.M41Val (c.121A > G), and p.M41Leu (c.121A > C) [1]. In addition, non-M41 gene mutations have been described, such as splice site mutations at exon 3 (c.118-2A > C, c.118-1G > C, c.118-9_118-2del) and mutations affecting codon 56 (c.167C > T) [13, 14]. In our case, patient 2 exhibited the common p.M41Thr mutation, while patient 1 who successfully discontinued HMA therapy had the UBA1 (c.118-1G > C) mutation, affecting the splice region at exon 3. Recently, Georgin-Lavialle [15] has described that the UBA1 p.M41Leu mutation is associated with a milder phenotype and a better 5-year survival rate compared to p.M41Val and p.M41Thr. However, a clear genotype-phenotype correlation, or even a correlation of certain mutations with responses to specific treatment strategies, has not yet been established.

The deep molecular response observed in our patients prompted us to consider treatment de-escalation with dose reduction of 5-Aza from 7 to 5 days, followed by treatment cycle extension to every 6 to 8 weeks, and ultimately treatment discontinuation in patient 1 after 44 months. Notably, he remained in sustained complete molecular remission 6 months after treatment discontinuation. However, the second patient temporarily exhibited a very low-level UBA1 mutation at month 30 during 5-Aza therapy, suggesting the persistence of UBA1-mutated cells in the quiescent stem cell pool, similar to the “leukemia stem cell persistence” observed in chronic myeloid leukemia [16]. Further prospective studies are necessary to clarify whether low-level minimal residual disease (MRD) or even complete clearance can guide safe treatment de-escalation. Close MRD monitoring in those patients is essential. Indeed, NGS in CD34+ -enriched pB cells provides a more sensitive detection of MRD compared to unsorted BM cells, as recently described [9, 17].

Co-mutations in VEXAS syndrome predominantly involve epigenetic regulators and splicing factors. DNMT3A and TET2, well-known for their association with inflammatory conditions, were the most commonly observed [18]. We also detected a low-level TET2 co-mutation in one of our patients, which may be indicative of clonal hematopoiesis due to its low VAF. However, due to multilineage dysplasia, increased blast cell count, and cytopenia, the diagnosis of MDS was established.

Of note, in both patients, 5-Aza not only addressed the VEXAS syndrome but also achieved complete remission of the associated MDS disease, including hematological, cytogenetic (case 1), and molecular (case 2) aspects. Neither additional myeloid mutations nor novel cytogenetic alterations could be observed during the follow-up phase. The exact relationship between the UBA1-mutant clone and the initiation of MDS is yet to be determined. It remains uncertain whether the myeloid neoplasm is primarily driven by the UBA1-mutant clone or whether the highly inflammatory microenvironment promotes clonal selection. 

In addition to azacitidine, further treatment approaches have been described in small VEXAS cohorts. Among them, the JAK1/2 inhibitor ruxolitinib is considered one of the most promising, which has successfully alleviated symptoms of VEXAS syndrome; however, no molecular remissions have been reported thus far. Indeed, a recent publication reported an increase in UBA1 burden under ruxolitinib, despite a highly favorable clinical response [8].